Fulranumab in patients with interstitial cystitis/bladder pain syndrome: observations from a randomized, double-blind, placebo-controlled study

Table 4 Treatment-emergent adverse events reported in ≥10% of patients in either treatment group

Adverse events are presented in decreasing order of incidence for the fulranumab group

ISSN: 1471-2490